Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px
Document › Details

ERS Genomics Ltd.. (3/3/21). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical". Dublin.

Organisations Organisation ERS Genomics Ltd.
  Organisation 2 Otsuka Pharmaceutical Co., Ltd.
  Group Otsuka (Group)
Products Product CRISPR-Cas9 technology
  Product 2 drug discovery
Index term Index term ERS Genomics–Zyme Communications: public relations, 202009 service existent by Zyme
Persons Person Rhodes, Eric (ERS Genomics 201606– CEO before Horizon Discovery since 201201 before Sigma-Aldrich + Sangamo Biosciences)
  Person 2 Odgaard, Katie (Zyme Communications 201108 Senior Account Manager before College Hill Life Sciences)
     


License to Nobel prize winning CRISPR technology supports internal research and development


ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 intellectual property today announced the signing of a license agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka). The license grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmannuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

Eric Rhodes, CEO of ERS Genomics, said: “We are extremely pleased to be able to provide Otsuka with access to the CRISPR/Cas9 license. We hope this brings significant value to Otsuka as it applies the technology to its internal programs.”

Financial details of the agreement are not disclosed.

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan.


ENDS


For high resolution images please contact Zyme Communications


Contacts

Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com

   
Record changed: 2022-02-05

Advertisement

Picture [iito] Fighting Customers 650x100px

More documents for ERS Genomics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top